RecruitingPhase 1NCT07619287

An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies

Sponsor

BeOne Medicines

Enrollment

118 participants

Start Date

Jun 23, 2026

Study Type

INTERVENTIONAL

Conditions

Myeloid Malignancy

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BG-75202 and a drug called Hypomethylation Agent (HMA) for people with myeloid malignancy. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBG-75202

Administered orally

DRUGHypomethylation Agent (HMA)

Administered Intravenous (IV) or Subcutaneous (SC)

Locations(16)

Concord Repatriation General Hospital

Concord, New South Wales, Australia

St George Hospital

Kogarah, New South Wales, Australia

Icon Cancer Centre Kurralta Park

Kurralta Park, South Australia, Australia

Austin Health

Heidelberg, Victoria, Australia

Linear Clinical Research

Nedlands, Western Australia, Australia

The First Hospital of Lanzhou University

Lanzhou, Gansu, China

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

The Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

The First Affiliated Hospital of Zhengzhou Universitysouth Branch

Zhengzhou, Henan, China

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

The First Affiliated Hospital of Nanchang University Branch Donghu

Nanchang, Jiangxi, China

The First Affiliated Hospital of Nanchang University Branch Xianghu

Nanchang, Jiangxi, China

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch

Tianjin, Tianjin Municipality, China

North Shore Hospital

Auckland, New Zealand

Auckland City Hospital

Auckland, New Zealand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07619287

Related Trials

A Telehealth Advance Care Planning Intervention

NCT058758051 location

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

NCT065944451 location

Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories

NCT072630741 location

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

NCT0450112012 locations

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

NCT061297342 locations